Chronic Lymphocytic Leukemia
New Approaches for a Common Disease
CLL and Minimal Residual Disease (MRD)
October 2008
Does immunohistochemistry (IHC) have a role in bone marrow specimens?
I would say that stains are often complementary to flow studies, but they are often hard to interpret in isolation away from flow studies. One also needs to be aware that T-cell nodules depleted of B-cells may be identified in patients who have been treated with Rituxan and clearly can be confused with CLL on a strict morphology basis.
What antibodies should be used for IHC?
There is no specific and easy answer. A variety of B-cell antibodies have been used, I would say that CD20 however has a minimal role because of the Rituxan effect; T-cell markers are also frequently done. However, CD5 may be hard to interpret in these cases.
Minimal Residual Disease (MRD) |
Jump to section:
- Introduction
- Goals Today
- CLL, MBL, and SLL Overview
- CLL: Evolution of Diagnostic Criteria
- Chronic B-Cell Lymphoproliferative Disorders: Prototypic Immunophenotype
- CLL: Dim sIg, dim CD20, CD5+ & CD23+
- "Copycat": MCL with CD5+/partial CD23+
- "Copycat": LPL with CD5+/CD23-
- Diagnosis of MBL & SLL: IWCLL
- Diagnostic Criteria: CLL, MBL, and SLL
- Diagnostic Criteria: CLL, MBL, and SLL
- Identification of MBL
- How will MBL be Recognized in Routine Clinical Practice?
- How is MBL Recognized in Routine Clinical Practice?
- Diagnostic Criteria: MBL in Clinical Practice
- MBL: Prevalence and Progression
- MBL: Summary
- Familial CLL
- MBL Case: Clinical History
- MBL Case: Peripheral Blood Immunophenotype
- MBL Case: Bone Marrow Biopsy
- Diagnosis Diagram
- CLL and Minimal Residual Disease (MRD)
- CLL and Minimal Residual Disease (MRD)
- CLL and Minimal Residual Disease (MRD)
- CLL MRD Case: Clinical History
- CLL MRD Case: Clinical History
- CLL MRD Case: Bone Marrow Biopsy
- CLL MRD Case: Bone Marrow Biopsy
- CLL MRD Case: PB Flow
- CLL MRD Case: BM Flow
- Goals Today
- Questions?
External
link
PDF
document
Excel
document
Word
document